Unicycive Therapeutics Reports $61.4M Cash Balance, Providing Runway Post-FDA Rejection
UNCY sits 50% above its 52-week low of $3.71.
Summary
Unicycive Therapeutics reported a preliminary cash balance of $61.4 million as of June 30, 2026, providing a critical financial buffer following the recent FDA rejection of its drug.
Key Events · Financing and Capital Events · UNCY
-
Cash Balance Update
The company reported a preliminary cash balance of approximately $61.4 million as of June 30, 2026.
-
Implied Capital Raise
This cash balance suggests the company raised approximately $35.5 million through its At-The-Market (ATM) program between March 31, 2026 (Q1 end) and June 30, 2026.
-
Post-FDA Rejection Context
The cash update follows the FDA's recent decision to decline approval for the company's drug, making this liquidity critical for extending the operational runway.
Analysis · UNCY · Life Sciences
This filing provides a crucial update on the company's cash position, reporting $61.4 million as of June 30, 2026. This cash balance is significant, especially coming immediately after the FDA declined approval for their key drug. The company has been actively raising capital through its ATM program, with this update implying approximately $35.5 million was raised between Q1 and the end of Q2. This cash provides essential liquidity and extends the company's operational runway following a major regulatory setback, which is critical for its continued operations and strategic planning.
At the time of this filing, UNCY was trading at $5.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $148.9M. The 52-week trading range was $3.71 to $8.74. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.